Report Description: Lateral Flow Assays Market Size, Trend, by Product (Kits & Reagents, Readers), by Sample Type (Blood, Urine, Saliva), by Application, by Technique, End Users, Region, Major Players – Global Forecast to 2030
Wissen Research analysed that the global lateral flow assays market was valued at USD 8.2 billion in 2024 and is projected to reach USD 12.6 billion by 2030, expected to grow at a CAGR of 7.5% during the forecast period, 2025-2030.
Global lateral flow assays market is anticipated to reach USD 12.6 bn by 2030 from USD 8.2 bn in 2024, growing at an annualized rate of 7.5% during the forecast period 2025-30 | Asia-Pacific and Africa are high-growth regions for LFAs, and firms that localize manufacturing, navigate diverse regulatory landscapes (e.g., CDSCO, SAHPRA), and build distribution networks will capitalize on rising demand for affordable, point-of-need diagnostics. | Asia-Pacific Asia-Pacific Lateral Flow Assay market is fuelled by surging demand for point-of-care diagnostics in healthcare systems and infectious disease management, and those that invest in local manufacturing facilities, ISO-certified quality systems, and region-specific regulatory strategies will capture growth in rapid testing solutions. |
Expanding applications of multiplexed LFAs in infectious disease and chronic condition testing are driving market growth, and companies investing in high-sensitivity conjugation chemistries and digital integration will gain competitive advantage through enhanced diagnostic accuracy and user compliance. | Development of novel biomarkers and non-invasive sampling methods is a key innovation trend in LFAs, and organizations prioritizing R&D in nanoparticle labels and microfluidic integration will lead in addressing unmet clinical needs and evolving consumer preferences. Supply chain vulnerabilities for nitrocellulose membranes and gold nanoparticles pose critical risks in the LFA market, but businesses proactively securing raw materials, adhering to ISO 13485 standards, and ensuring ethical sourcing will build stakeholder trust, differentiate as industry leaders, and enable sustainable growth. |
Drivers: Benefits of LFAs and Growing Demand for Decentralized Testing
The LFA market is driven by intrinsic benefits of lateral flow technology, such as quick results (<15 minutes), portability, and low infrastructure needs. At the same time, growing demand for decentralized healthcare solutions fueled by aging demographics, rural healthcare access disparities, and home-testing convenience is driving adoption in infectious disease screening, chronic disease monitoring, and point-of-need diagnostics.
Opportunities: Multiplexing and Digital Integration
The transition to precision diagnostics opens up opportunities for LFA manufacturers to create multiplexed panels with the ability to analyze several analytes (e.g., respiratory pathogens, cardiac biomarkers) simultaneously in one test. This phenomenon is augmented through integration with digital readers and AI-based analytics that support quantitative results, remote data exchange, and personalized health information that satisfies changing clinician and consumer demands.
Challenges: Supply Chain Fragility and Sensitivity Limitations
The LFA business is confronted with severe threats from supply chain exposures for important materials (e.g., nitrocellulose membranes, gold nanoparticles), enhanced by geopolitical interference and raw material rivalry. Furthermore, intrinsic sensitivities for low-abundance biomarkers and environmental fluctuations (e.g., humidity/temperature influences) limit performance in difficult sample types, with plastic waste due to single-use tests posing sustainability issues.
The global lateral flow assay (LFA) market, focused on rapid and point-of-care diagnostic testing, is experiencing steady growth driven by the increasing demand for quick, accurate, and accessible diagnostic solutions. The market is valued at USD 8.2 billion in 2024 and is projected to reach USD 12.6 billion by 2030, growing at a CAGR of approximately 7.5%. Key drivers include the rising prevalence of infectious diseases, the need for decentralized testing, and advancements in LFA technology enabling broader applications such as COVID-19 testing, pregnancy testing, and disease diagnostics. North America leads the market due to its extensive healthcare infrastructure and high adoption of rapid testing kits, while the Asia Pacific region is emerging as a significant growth area owing to expanding healthcare access and increasing disease burden. Ongoing technological innovations and the expanding scope of applications are expected to further propel market growth.
Kits and Reagents segment registered the largest market share in the lateral flow assays market by product type (2024)
Clinical testing segment held the largest market share in the lateral flow assays market by application in 2024
For example, acute care departments worldwide utilize more than 100 million troponin LFAs each year for suspected myocardial infarction, with results in < 15 minutes directly informing thrombolytic therapy or catheterization—illustrating life-saving scale. Additionally, large health systems such as Cleveland Clinic and Singapore General Hospital have multi-year supply agreements with manufacturers including Siemens Healthineers and Beckman Coulter to provide uninterrupted access to cardiac marker, TSH, and HbA1c LFAs for chronic disease monitoring on a routine basis.
North America projected to hold the largest growth rate in lateral flow market in the forecast period (2025-2030)
North America projected to hold the largest growth rate in the lateral flow assay market (2025–2030), fueled by rapid regulatory innovation, advanced healthcare infrastructure, and early adoption of next-generation diagnostic technologies. This growth stems from accelerated FDA approvals for novel LFA applications, integration with digital health ecosystems, and expanding use beyond traditional clinical settings into veterinary, food safety, and environmental monitoring. Key verticals driving momentum include precision diagnostics, decentralized health networks, and biosecurity preparedness.
For instance, the FDA’s Breakthrough Device Program has fast-tracked multiplexed LFAs for sepsis and antibiotic resistance, enabling deployment in U.S. emergency departments within 6 months of development—demonstrating regulatory agility unmatched globally. Furthermore, tech giants like Apple and Google have partnered with LFA manufacturers (e.g., Abbott, QuidelOrtho) to embed smartphone-based readers into consumer health platforms, transforming home testing for cardiac biomarkers and infectious diseases into scalable, data-driven ecosystems.
Major players operating in lateral flow assay market are:
Note: The price above given is from the company’s websites or third-party websites.
Sources: Secondary Research
“The inability of conventional LFAs to reliably detect low-abundance biomarkers in viscous or heterogeneous samples—like saliva or whole blood—is forcing manufacturers to invest heavily in enhanced nanoparticle conjugates and signal amplification chemistries, particularly for early-stage cancer and neurodegenerative disease applications.”
Senior Scientist – Leading Diagnostic Manufacturer (Europe)
“Geopolitical disruptions and monopolistic control over nitrocellulose membrane production are making CDMOs and test developers prioritize backward integration, with companies like Abbott and QuidelOrtho now acquiring raw material suppliers to secure multi-year supply certainty for gold nanoparticles and buffer reagents.”
VP Procurement – Global LFA Manufacturer (North America)
“Divergent FDA, EMA, and PMDA requirements for validating multiplexed LFAs—especially those combining infectious disease and chronic condition markers—are adding 12–18 months to development timelines, forcing firms to prioritize single-analyte tests or pursue region-specific approvals first.”
Head of Regulatory Affairs – Emerging Diagnostic Company (Asia-Pacific)
“The push for smartphone-connected quantitative LFAs is raising technical and validation costs beyond the reach of small innovators, as FDA now requires cybersecurity risk assessments and cloud-compliance certifications for any test with Bluetooth or app connectivity, effectively consolidating the market around players with deep software expertise.”
CTO – Point-of-Care Testing Startup (North America)
Sources: Primary Research and Wissen Research Analysis.
Note: Above mention is non-exhaustive samples of the primary insights.
Particulars | Details |
Report | Lateral Flow Assays Market |
Forecast Period | 2025-2030 |
Base Year | 2024 |
Format | |
Market Size (2024) | USD 8.2 Billion |
CAGR (2025-2030) | 7.5% |
Number of Pages | 160 |
Number of Tables | 155 |
Number of Figures | 35 |
Key Segments | Lateral Flow Assays Market by Product (Kits and Reagent, Readers, Clinical Diagnostics Lateral Flow Readers Market, By Type) Lateral Flow Assays Market by Application (Clinical Testing, Veterinary Diagnostics, Food Safety & Environment Testing, Drug Development & Quality Testing) Lateral Flow Assays Market by Technique (Sandwich Assays, Competitive Assays, Multiplex Detection Assays) Lateral Flow Assays Market by Sample Type (Blood Samples, Urine Samples, Saliva Samples) Lateral Flow Assays Market by End Users (Hospitals and Clinics, Home Care Settings, Diagnostics Laboratories, Pharmaceutical & Biotechnology Companies) |
Regions Covered | § North America: US and Canada § Europe: Germany, UK, France, Italy, Spain, and Rest of the Europe § Asia-Pacific: China, Japan, India, South Korea, Australia and New Zealand, and Rest of the Asia-Pacific § Latin America § Middle East and Africa |
Key Players Covered (Majority Share Holders) | Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Germany), QuidelOrtho Corporation (US), Danaher Corporation (US), Siemens AG (Germany), Becton, Dickinson and Company (US), bioMérieux SA (France), Thermo Fisher Scientific Inc. (US), PerkinElmer Inc (US), QIAGEN N.V. (Netherlands) |
Other Players | Merck KGaA (Germany), Hologic, Inc. (US), Abcam plc (UK), Surmodics Inc. (US), Chembio Diagnostics, Inc. (Biosynex) (US), OraSure Technologies (US), DCN Diagnostics (US), Polysciences Inc. (US), Abingdon Health (UK), Oranoxis Inc. (US), Aesku.Group GmbH (Germany), Bio Group Medical System S.r.l (Italy), Pharmact GmbH (Germany), Diesse Diagnostica Senese S.p.A. (Italy), Xiamen Biotime Biotechnology Co., Ltd. (China) |
1. INTRODUCTION
1.1. KEY OBJECTIVES
1.2. DEFINITIONS
1.2.1. IN SCOPE
1.2.2. OUT OF SCOPE
1.3. SCOPE OF THE REPORT
1.4. SCOPE RELATED LIMITATIONS
1.5. KEY STAKEHOLDERS
2. RESEARCH METHODOLOGY
2.1. RESEARCH APPROACH
2.2. RESEARCH METHODOLOGY / DESIGN
2.3. MARKET SIZE ESTIMATION APPROACHES
2.3.1. SECONDARY RESEARCH
2.3.2. PRIMARY RESEARCH
2.3.2.1. KEY INSIGHTS FROM INDUSTRY EXPERTS
2.4. DATA VALIDATION & TRIANGULATION
2.5. ASSUMPTIONS OF THE STUDY
3. EXECUTIVE SUMMARY & PREMIUM CONTENT
3.1. GLOBAL MARKET OUTLOOK
3.2. KEY MARKET FINDINGS
4. MARKET OVERVIEW
4.1. LATERAL FLOW ASSAYS: OVERVIEW
4.1.1. INTRODUCTION
4.1.2.KEY FEATURES AND FUNCTIONALITIES
4.1.3.BENEFITS OF LATERAL FLOW ASSAYS
4.1.4.TYPES OF LATERAL FLOW ASSAYS
4.2. MARKET DYNAMICS
4.2.1. MARKET DRIVERS
4.2.2. MARKET OPPORTUNITIES
4.2.3. RESTRAINTS/CHALLENGES
4.3. END USER PERCEPTION
4.4. NEED GAP ANALYSIS
4.5. SUPPLY CHAIN / VALUE CHAIN ANALYSIS
4.6. INDUSTRY TRENDS
4.7. PORTER’S FIVE FORCES ANALYSIS
4.8. REGULATORY LANDSCAPE
4.8.1.NORTH AMERICA
4.8.2.EUROPE
4.8.3.ASIA PACIFIC
5. PATENT ANALYSIS
5.1. TOP ASSIGNEES
5.2. GEOGRAPHY FOCUS OF TOP ASSIGNEES
5.3. LEGAL STATUS
5.4. TECHNOLOGY EVOLUTION
5.5. KEY PATENTS
5.6. PATENT TRENDS AND INNOVATIONS
6. GLOBAL LATERAL FLOW ASSAYS MARKET, BY PRODUCT (2024-2030, USD MILLION)
6.1. KITS AND REAGENT
6.2. READERS
6.2.1.DIGITAL/HANDHELD READERS
6.2.2.BENCHTOP READERS
6.2.3.DISPOSABLE AND RESUABLE
6.3. CLINICAL DIAGNOSTICS LATERAL FLOW READERS MARKET, BY TYPE
7. GLOBAL LATERAL FLOW ASSAYS MARKET, BY APPLICATION (2024-2030, USD MILLION)
7.1. CLINICAL TESTING
7.1.1.INFECTIOUS DISEASE TESTING
7.1.1.1. MOSQUITO-BORNE DISEASES
7.1.1.2. COVID-19
7.1.1.3. INFLUENZA
7.1.1.4. SEXUALLY TRANSMITTED INFECTIONS
7.1.1.5. HEPATITIS
7.1.1.6. TUBERCULOSIS
7.1.1.7. OTHER INFECTIOUS DISEASES
7.1.2.CARDIAC MARKER TESTING
7.1.2.1. TROPONIN I & T
7.1.2.2. CK-MB
7.1.2.3. BNP & NT-PROBNP
7.1.2.4. MYOGLOBIN
7.1.2.5. D-DIMER
7.1.2.6. OTHER CARDIAC MARKER TESTS
7.1.3.PREGNANCY & FERTILITY TESTING
7.1.3.1. PREGNANCY TESTING
7.1.3.2. FERTILITY TESTING
7.1.4.CHOLESTEROL/LIPID TESTING
7.1.5.DRUGS-OF-ABUSE TESTING
7.1.6.OTHER CLINICAL TESTS
7.2. VETERINARY DIAGNOSTICS
7.3. FOOD SAFETY & ENVIRONMENT TESTING
7.4. DRUG DEVELOPMENT & QUALITY TESTING
8. GLOBAL LATERAL FLOW ASSAYS MARKET, BY TECHNIQUE (2024-2030, USD MILLION)
8.1. SANDWICH ASSAYS
8.2. COMPETITIVE ASSAYS
8.3. MULTIPLEX DETECTION ASSAYS
9. GLOBAL LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE (2024-2030, USD MILLION)
9.1. BLOOD SAMPLES
9.2. URINE SAMPLES
9.3. SALIVA SAMPLES
9.4. OTHER SAMPLES
10. GLOBAL LATERAL FLOW ASSAYS MARKET, BY END USER (2024-2030, USD MILLION)
10.1. HOSPITALS AND CLINICS
10.2. HOME CARE SETTINGS
10.3. DIAGNOSTICS LABORATORIES
10.4. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.5. OTHER END USERS
11. GLOBAL LATERAL FLOW ASSAYS MARKET, BY REGION (2024-2030, USD MILLION)
11.1. NORTH AMERICA
11.1.1. US
11.1.2. CANADA
11.2. EUROPE
11.2.1. GERMANY
11.2.2. FRANCE
11.2.3. SPAIN
11.2.4. ITALY
11.2.5. UK
11.2.6. REST OF THE EUROPE
11.3. ASIA-PACIFIC
11.3.1. CHINA
11.3.2. JAPAN
11.3.3. INDIA
11.3.4. AUSTRALIA AND NEW ZEALAND
11.3.5. SOUTH KOREA
11.3.6. REST OF THE ASIA-PACIFIC
11.4. MIDDLE EAST AND AFRICA
11.5. LATIN AMERICA
12. COMPETITIVE ANALYSIS
12.1. PRODUCT PIPELINE: LATERAL FLOW ASSAYS
12.2. KEY PLAYERS FOOTPRINT ANALYSIS
12.3. MARKET SHARE ANALYSIS (2023/2024)
12.4. REGIONAL SNAPSHOT OF KEY PLAYERS
12.5. R&D EXPENDITURE OF KEY PLAYERS
13. COMPANY PROFILES
13.1. ABBOTT LABORATORIES (US)
13.1.1. BUSINESS OVERVIEW
13.1.2. PRODUCT PORTFOLIO
13.1.3. FINANCIAL SNAPSHOT
13.1.4. RECENT DEVELOPMENTS
13.1.4.1. MERGER/ACQUISITIONS
13.1.4.2. PRODUCT APPROVAL/LAUNCHES
13.1.4.3. PARTNERSHIP/COLLABORATIONS/AGREEMENTS
13.1.4.4. EXPANSIONS
13.2. F. HOFFMANN-LA ROCHE LTD (GERMANY)
13.3. QUIDELORTHO CORPORATION (US)
13.4. DANAHER CORPORATION (US)
13.5. SIEMENS AG (GERMANY)
13.6. BECTON, DICKINSON AND COMPANY (US)
13.7. BIOMÉRIEUX SA (FRANCE)
13.8. THERMO FISHER SCIENTIFIC INC. (US)
13.9. PERKINELMER INC (US)
13.10. QIAGEN N.V. (NETHERLANDS)
13.11. OTHER PLAYERS
13.11.1. MERCK KGAA (GERMANY)
13.11.2. HOLOGIC, INC. (US)
13.11.3. ABCAM PLC (UK)
13.11.4. SURMODICS INC. (US)
13.11.5. CHEMBIO DIAGNOSTICS, INC. (BIOSYNEX) (US)
13.11.6. ORASURE TECHNOLOGIES (US)
13.11.7. DCN DIAGNOSTICS (US)
13.11.8. POLYSCIENCES INC. (US)
13.11.9. ABINGDON HEALTH (UK)
13.11.10. ORANOXIS INC. (US)
13.11.11. AESKU.GROUP GMBH (GERMANY)
13.11.12. BIO GROUP MEDICAL SYSTEM S.R.L (ITALY)
13.11.13. PHARMACT GMBH (GERMANY)
13.11.14. DIESSE DIAGNOSTICA SENESE S.P.A. (ITALY)
13.11.15. XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD. (CHINA)
14. APPENDIX
14.1. INDUSTRY SPEAK
14.2. QUESTIONNAIRE/DISCUSSION GUIDE
14.3. AVAILABLE CUSTOM WORK
14.4. ADJACENT STUDIES
14.5. AUTHORS
15. REFERENCES
Lateral flow assays market represents a series of products and technologies designed for rapid, point-of-need detection of target analytes in biological samples. Lateral flow assays are applied to diagnose diseases, monitor biomarkers, detect pathogens, and test for contaminants, providing advantages like speed, portability, ease of use, and cost-effectiveness. The market serves diverse sectors including healthcare, veterinary, food safety, environmental testing, and biodefense, encompassing components such as nitrocellulose membranes, conjugate pads, sample pads, and reader systems. Key market features include single-use test strips, multiplexing capabilities, and digital integration. The market is driven by rising demand for decentralized diagnostics, pandemic preparedness needs, and technological advancements in assay sensitivity. Emerging trends like smartphone-connected readers, multiplexed panels, and non-invasive sampling methods are accelerating innovation and adoption globally.
FIGURE: LATERAL FLOW ASSAYS MARKET SEGMENTS
Sources: Company Websites and Wissen Research Analysis
Key Stakeholders
Key Study Objectives
Research Methodology
The objective of the study is to analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track company developments such as product launches and approvals, expansions, and collaborations of the leading players, the competitive landscape of the lateral flow assays market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches will be used to estimate the market size. To estimate the market size of segments and sub segments the market breakdown and data triangulation will be used.
FIGURE: RESEARCH DESIGN
Sources: Wissen Research Analysis
Research Approach
Collecting Secondary Data
The secondary research data collection process involves the usage of secondary sources, directories, databases, annual reports, investor presentations, and SEC filings of companies. Secondary research will be used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the lateral flow assays market. A database of the key industry leaders will also be prepared using secondary research.
Collecting Primary Data
The primary research data will be collected after acquiring knowledge about the lateral flow assays market scenario through secondary research. A significant number of primary interviews will be conducted with stakeholders from both the demand side and supply side (including various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers) across major countries of North America, Europe, Asia Pacific, and Rest of the World. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.
Market Size Estimation
All major developers offering various lateral flow assays will be identified at the global/regional level. Revenue mapping will be done for the major players, which will further be extrapolated to arrive at the global market value of each type of segment. The market value of lateral flow assays market will also split into various segments and sub segments at the region level based on:
Research Design
After arriving at the overall market size-using the market size estimation processes-the market will be split into several segments and sub segment. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub segment, the data triangulation, and market breakdown procedures will be employed, wherever applicable. The data will be triangulated by studying various factors and trends from both the demand and supply sides in the lateral flow assays industry.
The global market for lateral flow assays market was valued at USD 8.2 billion in 2024.
The global lateral flow assays market is anticipated to grow at an annual growth rate of 7.5% from 2025 to 2030 to reach USD 12.6 billion, by 2030.
Leading players within the lateral flow assays market are Abbott Laboratories (US), F. Hoffmann-La Roche Ltd (Germany), QuidelOrtho Corporation (US), Danaher Corporation (US) and Siemens AG (Germany).
The lateral flow assays market is highly consolidated, characterized by a tiered structure where global leaders dominate high-value segments, while regional specialists and niche players maintain competitive positions through technological differentiation and agility. Strategic mergers, acquisitions, and vertical integration drive consolidation, yet the market retains dynamism through specialized innovation and regional fragmentation.
